Corona Remedies Limited announced on May 11, 2026, that its Board of Directors has recommended a final dividend of ₹10 per equity share for the financial year ended March 31, 2026. The dividend represents a payout of 100% on the face value of ₹10 per share and remains subject to shareholder approval at the company's ensuing Annual General Meeting.
Dividend Details and Yield
At the current market price of ₹1,765, the declared dividend of ₹10 per share translates to a dividend yield of approximately 0.57%. The stock closed with a gain of ₹52.70, or 3.08%, on the day of the announcement, touching its 52-week high of ₹1,807.40 intraday on May 11, 2026. The 52-week low stands at ₹1,336.60, recorded on December 23, 2025, placing the current price 32% above that trough and near the upper end of its annual trading range.
Dividend History and Trend
Available NSE filings show this as the first disclosed dividend entry in the company's dividend history data on the exchange platform. Corona Remedies was listed relatively recently under ISIN INE02ZQ01018 and is part of the NIFTY IPO, NIFTY Total Market, and NIFTY Microcap 250 indices, reflecting its status as a newer entrant to the listed space. The absence of a prior-year comparable dividend in exchange records means a year-on-year growth comparison cannot be established at this stage.
Valuation Context
The company's price-to-earnings ratio is currently not available in exchange data, and a sector PE benchmark has likewise not been disclosed, limiting direct valuation comparison at this time. The company's market capitalisation stands at ₹10,794.76 Cr, positioning it firmly within the microcap segment of the Indian pharmaceutical universe.
Board Meeting Outcomes
Beyond the dividend, the May 11 board meeting addressed several governance and compliance items of relevance to shareholders:
- Approval of audited standalone and consolidated financial results for Q4 and the full year ended March 31, 2026
- Appointment of Walker Chandiok and Co LLP as Statutory Auditor
- Re-appointment of Dhara Patel as Secretarial Auditor
- Appointment of Shah and Shah Associates as Internal Auditor for FY2026-27
- Re-appointment of Manish B. Analkat as Cost Auditor for FY2026-27
- Re-appointment of Dr. Kirtikumar Mehta (DIN: 00385658) as Non-Executive Director and Chairman for five consecutive financial years from April 1, 2027
Trading Activity and Delivery Data
On the day of the announcement, 47,515 shares were traded on the NSE. The delivery percentage stood at 32.88%, indicating that roughly one-third of the day's traded volume resulted in actual share transfers rather than intraday squaring off. Daily volatility is recorded at 1.31%, suggesting moderate price fluctuation relative to the stock's average session movement.
The final dividend payout, once approved by shareholders at the AGM, will be disbursed as per the record date to be announced subsequently. Investors holding shares as of that record date will be eligible to receive ₹10 per share.